EHDN2021 – European Huntington's Disease Network

The EHDN 2021 Remote Meeting

Dear Friend of EHDN,
On behalf of the members of the Program and Organizing Committee and the Executive Committee of the European Huntington´s Disease Network we want to thank you for your participation in the 3 half-day EHDN Remote Meeting on

Thursday – Saturday, September 9-11, 2021

Program Download [PDF]

Meeting-Report: EHDN2021-Report

Abstracts
[brief poster summaries]
Published meeting abstracts in a supplement edition of the Journal of Neurology Neurosurgery & Psychiatry [JNNP]

Posters: EHDN2021-Poster

Meeting recordings: DAY1, DAY2, DAY3

DAY 1

WELCOME AND INTRODUCTION + EHDN Business Anne Rosser, Jean-Marc Burgunder, Astri Arnesen	</p> <p>	KEYNOTE SESSION I: From fruitfly biorhythm genetics to Huntington’s Charalambos P. Kyriacou	</p> <p>
PLENARY SESSION I: Genetic modifiers of HD: DNA damage and somatic expansion of repeats; Chaired by: Lesley Jones and Davina Hensman
Gene editing for expanded CAG/CTG repeat disorders: making a long story short Vincent Dion	<br />	Using histone deacetylase 3 inhibition to rein in HD expansion mutations Bob Lahue	<br />
Dissecting Genetic Modifiers of HD: Towards Understanding Mechanism Vanessa Wheeler	<br />
PLENARY SESSION II: Cognition; Chaired by: Jaime Kulisevsky and Saul Maritnez-Horta
Session presentation Saul Martinez-Horta	<br />	Visual system integrity in Huntington’s disease Michael Orth	<br />
Hippocampal-dependent memory in Huntington’s disease Julie Stout	<br />	Q&A	<br />
Closing Remarks Jaime Kulisevsky	<br />
SHORT COMMUNICATIONS I: Chaired by: Esther Cubo and Lauren Byrne
Research Participation: The View of Persons at Risk and Persons with Premanifest HD Filipa Júlio	<br />	Huntington’s Disease Burden of Illness (HDBOI): Study Methodology, Sample Representativeness and Fieldwork Risk Mitigation Strategy During the COVID-19 Pandemic Idaira Rodríguez	<br />
Comparison of models for estimating Age at motor onset in HD Peter Holmans	<br />	Skill-Based Dysphagia Training as an Intervention for Individuals with HD Emma Burnip	<br />
Introducing JOIN-HD: The Juvenile Onset Initiative for Huntington’s Disease Rebecca Mason	<br />
Announcement and Round-up
HDYO donation Matthew Ellison	<br />	ROUND-UP and Goodbye for the day Hosts Anne Rosser and Jean-Marc Burgunder with Sandrine Humbert and Bernhard Landwehrmeyer	<br />

DAY 2

Announcement
MDS/EHDN teaching course Michael Orth	<br />
PLENARY SESSION III: Clinical Trial Session; Chaired by: Ralf Reilmann and Dina de Sousa
Roche – An update from the tominersen clinical development programme Scott Schobel	<br />	SIGNAL/Vaccinex – results and lessons learnt Maurice Zauderer	<br />
SELECT-HD, an adaptive first-in-human clinical trial to evaluate WVE-003, an investigational allele-selective mHTT-lowering oligonucleotide, in early manifest Huntington’s disease Vissia Viglietta	<br />	UniQure – An update on HD-GeneTRX-1 and HD-GeneTRX-2 – Phase 1 / 2 Clinical Trials of AMT-130 Gene Therapy for early stage HD David Cooper	<br />
Development of TTX-3360 to prevent onset and/or progression in HD and other Repeat Expansion Disorders by Halting Somatic Expansion Irina Antonijevic	<br />	PROOF-HD – update on the status of the phase III clinical trial of pridopidine aiming to improve global function in early stage HD Michael Hayden	<br />
PANEL DISCUSSION: What are the lessons learned in the drug development process?; Chaired by: Ralf Reilmann and Dina de Sousa
Speakers from Plenary Session III	<br />
PARALLEL SESSION: Neuro-Development; Chaired by: Sandrine Humbert and Silvia Gines
Huntington’s disease alters cortical development in mouse and human Monia Barnat	<br />	Pediatric onset Huntington disease: neuro developmental delay or early neurodegeneration? Ferdinando Squitieri	<br />
Specific developmental alterations of striatal subpopulations in Huntington’s disease Josep Canals	<br />
PARALLEL SESSION: Multidisciplinary care; Chaired by: Marleen van Walsem and Ruth Veenhuizen
Introduction: Multidisciplinary care and treatment: focus on care in advanced stages: challenges and approaches for managing Ruth Veenhuizen	<br />	Challenges and practise-based approaches in professional advanced care Marleen van Walsem	<br />
Patients with Huntington’s disease living in a nursing home: characteristics, functioning, and gender differences Ruth Veenhuizen	<br />	Passivities of daily living Manon van Kampen	<br />
Discussion	<br />
SHORT COMMUNICATIONS II Chaired by: Ahmad Aziz and Maria Björkqvist
Fronto-Striatal Circuits for Cognitive Flexibility in far from Onset Huntington’s Disease: Evidence from the Young Adult Study Christelle Langley	<br />	Mutation-Related Apparent Myelin, not Axon Density, Drives White Matter Pathology in Premanifest Huntington’s Disease: Evidence from in Vivo Ultra-Strong Gradient MRI Chiara Casella	<br />
A Different Depression: Antidepressant Efficacy and Cognitive Mechanisms of Mood Disorder in Huntington’s Disease Duncan McLauchlan	<br />	Clinical Translation of Stem Cell Therapies for Huntington’s Disease (HD) Anne Rosser	<br />
Triheptanoin is Associated with Clinical Stability and Decreased Caudate Atrophy in HD Fanny Mochel	<br />
ROUND-UP
Goodbye for the day Hosts Anne Rosser and Jean-Marc Burgunder with Ahmad Aziz and Dina de Sousa	<br />

DAY 3

SHORT COMMUNICATIONS III: Chaired by Kathrin Reetz and Jean-Marc Burgunder
FAN1 Controls CAG Repeat Expansion in Huntington’s Disease by Dual Functions, MLH1 Retention and Nuclease Activity Joseph Hamilton	</p> <p>	Striatal Procedural Memory-Induced Transcriptome and Epigenome are Severely Impaired in Huntington’s Disease Mice Rafael Alcalá-Vida	</p> <p>
A New In Vivo and In Vitro Single-Cell Atlas of Developing Medium Spiny Neurons to Guide Future Improvements for Huntington Disease Cell-Replacement Therapies and Disease Modelling Vittoria Bocchi	<br />	Huntingtin-Mediated Axonal Transport Requires Arginine Methylation by PRMT6 Alice Migazzi	<br />
The ‘Hold me Tight’ Relationship Program for Couples Facing Huntington’s Disease Lucienne van der Meer	<br />
PARALLEL SESSION: Digital Technologies to Advance Assessment and Care in HD; Chaired by: Alzbeta Mühlbäck and Monica Busse
Introduction to the session: Landscape View of the Field Monica Busse	<br />	IDEA-FAST Ralf Reilmann	<br />
eHealth Platform for HD overview Pearl van Lonkhuizen	<br />	DOMINO-HD overview Philippa Morgan-Jones	<br />
Panel Discussion: Ethical & practical challenges All speakers and chairs	<br />
PARALLEL SESSION: Sleep, circadian rhythm and metabolism in HD; Chaired by: Patrick Weydt and Asa Petersen
Introduction to the topic by the chairs	<br />	Sleep and metabolism in Huntington disease Roger Barker	<br />
Clock genes and circadian rhythm Charalambos P. Kyriacou	<br />	Targeting cholesterol metabolism as a therapy for Huntington disease Sandrine Betuing	<br />
Summary and practical tips	<br />
PLENARY SESSION IV: Upcoming Clinical Trials; Chaired by: Jean-Marc Burgunder and Bernhard Landwehrmeyer
SOM Biotech Catherine Scart-Grès	<br />	Novartis Beth Borowsky	<br />
Current Gene therapeutic efforts: an overview Bernhard Landwehrmeyer	<br />	Enroll-HD Platform Studies Olivia Handley	<br />
HDClarity Ed Wild	<br />	Panel discussion all speakers of session IV	<br />
KEYNOTE SESSION II: Outlook; Chaired by: Dina de Sousa and Giorgos Papantoniou
New staging system in HD extending the window of testing and treatment Cristina Sampaio	<br />	Q&A	<br />
ROUND-UP and Goodby for the day; Chaired by: Anne Rosser and Jean-Marc Burgunder
Historical perspective Tom Bird	<br />	Goodbye Hosts Anne Rosser and Jean-Marc Burgunder with Tom Bird, Astri Arnesen	<br />

Contact:
If you have any questions, please contact us at ehdn2021@euro-hd.net.